BONDRONAT - OPYT PRIMENENIYa U BOL'NYKh S KOSTNYMI METASTAZAMI RAKA MOLOChNOY ZhELEZY
- Authors: Semenov N.N1
-
Affiliations:
- Issue: No 8 (2014)
- Pages: 62-64
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/286938
- ID: 286938
Cite item
Open Access
Access granted
Abstract
Bondronat (ibandronic acid) is a representative of group of bisphosphonates, which exists both in intravenous and in oral forms, that significantly expands the possibilities of its application. In patients with bone metastases from breast cancer (BC), approximately equal efficacy of two dosage forms of Bondronat (6 mg intravenously every 4 weeks and 50 mg/day per os continuously) in the prevention of skeletal events, expressed in reducing their risk by 40 % was demonstrated. Recent studies show that Bondronat is an appropriate alternative to zoledronate in the therapy of bone metastases from breast cancer. Application of oral form of Bondronat in patients who do not require intravenous administration of drugs and frequent monitoring of peripheral blood (for example, hormonal treatment of breast cancer) is particularly promising. Almost complete absence of renal toxicity of intravenous form of Bondronat allows to use intensive regimens (for 3 consecutive days) for painful bone metastases, without any problems.
Keywords
Full Text
References
- Body J.J., Diel I.J., Lichinitser M.R., et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. 2003; 14: 1399-405.
- Body J.J., Diel I.J., Lichinitser M.R., et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br. J. Cancer. 2004; 90: 1133-37.
- von Moos R., Thrlimann B., Caspar C.B., et al. Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study. Ann. Oncol. 2008; 19(7): 1266-70.
- Barrett-Lee P., Casbard A., Abraham J., et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol. 2014; 15(1): 114-22.
- Nelson A., Fenlon D., Morris J., et al. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials. 2013; 14: 325.
- Palmieri C., Fullarton J.R., Brown J. Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. Clin. Cancer Res. 2013; 19: 6863-72.
- Body J.J., Lichinitser M., Tjulandin S., et al. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann. Oncol. 2007; 18: 1165-71.
- Meattini I., Bruni A., Scotti V., et al. Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature. J. Chemother. 2010; 22(1): 58-62.
- Jagdev S., Berry H., Newsham A., et al. Clodronate compared to ibandronate breast cancer bone metastases patient preference study. J. Clin. Oncol. 2007; 25( 18S): 1068. ASCO Annual Meeting Proceedings (Post-Meeting Edition).
- Schmidt M., Hesse T., Kuehnle H., et al. Ibandronate Shows Marked Pain Relief and a Favorable Renal Safety Profile - Updated Results of a Non Interventional Study in Breast Cancer Patients with Metastatic Bone Disease. Cancer Res. 2009; 69(24): 3.
- Altundag K., Dizdar O., Ozsaran Z., et al. Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain. Onkologie. 2012; 35(5): 254-58.
- Ren S., Zhang L., Zhou C., et al. The efficacy and safety of loading dose ibandronate in the treatment of non-small cell lung cancer metastatic bone pain (MBP). J. Clin. Oncol. 2008; 26(15S): 19127. ASCO Annual Meeting Proceedings (Post-Meeting Edition).
- Mancini I., Dumon J.C., Body J.J. Efficacy and Safety of Ibandronate in the Treatment of Opioid-Resistant Bone Pain Associated With Metastatic Bone Disease: A Pilot Study. J. Clin. Oncol. 2004; 22(17): 3587-92.
- Vassiliou V., Kalogeropoulou C., Christopoulos C., et al. Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int. J. Radiat. Oncol. Biol. Phys. 2007; 67(1): 264-72.
- Heras P., Karagiannis S., Kritikos K., et al. Ibandronate is effective in preventing skeletal events in patients with bone metastases secondary to colorectal carcinoma. J. Clin. Oncol. 2005; 23(16S): 3639. ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Supplementary files
